LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)

Rhea-AI Summary

LakeShore Biopharma (Nasdaq: LSB) has launched a novel packaging solution for its YSJA™ rabies vaccine (Vero cell) following regulatory approval on April 15, 2025. The innovative packaging features needle-free reconstitution technology, addressing key safety challenges in vaccine administration.

The new design includes specialized components for automatic clamping, needle-free reconstitution, and new needle injection, enhancing vaccination safety and convenience. Key benefits include:

• Reduced risk of compounding contamination
• Lower occupational exposure for medical staff
• Decreased needle tip pain
• Minimized particle pollution and inflammation risk

This marks the first commercial application of advanced liquid transfer device technology in China's rabies vaccine market, with nationwide distribution set to begin within weeks of the April 18, 2025 launch meeting in Changsha, Hunan Province.

Positive

• First-to-market advantage with novel packaging technology in China's rabies vaccine sector
• Regulatory approval secured for innovative vaccine delivery system
• Imminent nationwide distribution expansion in China

Negative

• None.

News Market Reaction – LSB

-5.00%

1 alert

-5.00% News Effect

On the day this news was published, LSB declined 5.00%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Revolutionizing Vaccination Safety with Needle-Free Reconstitution Technology

BEIJING, April 23, 2025 /PRNewswire/ -- On April 18, 2025, LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company") successfully held the 2025 CSO ("Contract Sales Organization") Annual Meeting and the launch meeting of YSJA™ rabies vaccine (Vero cell) novel packaging solution (liquid drug transfer device) in Changsha, Hunan Province. Approved for lot release by regulatory authorities on April 15, 2025, the new formulation will begin nationwide distribution in China within weeks, addressing critical safety challenges in vaccine administration.

To address pain points such as compounding contamination, occupational exposure of medical staff and needle tip pain, the novel packaging YSJA™ vaccine has been upgraded accordingly. In addition, the novel packaging product is equipped with specially designed clasp, puncture device and suction head, which can realize automatic clamping, needle-free reconstitution and new needle injection, improve the convenience and safety of vaccination, reduce the risk of particle pollution and inflammation, and protect medical staff from needlestick injuries. The new packaging product of YSJA™ rabies vaccine has filled the gap in the Chinese market, and its innovative design was highly recognized by the CSOs participating in the conference.

"The YSJA™ packaging innovation represents humanized design in vaccine delivery," stated Mr. Wang Xu, CEO of LakeShore Biopharma. "By leveraging closed sterile connection technology, this novel design will gradually address the industry pain points of "occupational exposure and pollution risk" in the traditional liquid preparation process. This launch marks the first commercial application of such advanced liquid transfer device in China's rabies vaccine market, filling a significant unmet need." With rabies remaining a critical public health threat in endemic regions, the company will continue to be committed to empowering medical safety with science and technology in the future.

For media inquiries, please contact:
Website: https://investors.lakeshorebio.com/
Email: ir@lakeshorebio.com 

View original content:https://www.prnewswire.com/news-releases/lakeshore-biopharma-announces-the-official-launch-of-a-novel-packaging-solution-for-ysja-rabies-vaccine-vero-cell-302435932.html

SOURCE LakeShore Biopharma Co., Ltd.

FAQ

What are the key features of LSB's new YSJA rabies vaccine packaging solution?

The new packaging includes automatic clamping, needle-free reconstitution, and specialized injection components that reduce contamination risk, minimize occupational exposure, and improve vaccination safety.

When will LSB's new YSJA rabies vaccine packaging be available in China?

Following regulatory approval on April 15, 2025, nationwide distribution in China will begin within weeks of the April 18, 2025 launch.

How does LSB's new vaccine packaging improve safety for healthcare workers?

The packaging's closed sterile connection technology and needle-free reconstitution system protect medical staff from needlestick injuries and reduce occupational exposure risks.

What market advantage does LSB gain with the new YSJA packaging solution?

LSB becomes the first company to commercially implement advanced liquid transfer device technology in China's rabies vaccine market, filling an unmet market need.